<DOC>
	<DOCNO>NCT01037478</DOCNO>
	<brief_summary>The purpose study determine whether Resminostat ( 4SC-201 ) effective safe treatment relapse refractory Hodgkin 's Lymphoma .</brief_summary>
	<brief_title>Resminostat ( 4SC-201 ) Relapsed Refractory Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Main Patients must histological cytological evidence Hodgkin 's Lymphoma ( subtypes acceptable ) Patients must relapse refractory Hodgkin 's Lymphoma ( HL ) define relapse follow initial therapy lack response first line therapy treatment secondline ( salvage therapy ) . Patients may also undergo highdose chemotherapy autologous stem cell transplantation least 12 week prior study entry Patients must measurable anatomical disease present CT scan Patients must ECOG Performance Score 0 , 1 2 Main Patients receive previous treatment HDAC inhibitor Patients undergone allogeneic hematopoietic stem cell transplantation Patients know suspected involvement CNS HL Patients treat agent know prolong QT interval confirm QTcF &gt; 450 msec Patients history malignancy unless undergone definitive treatment 5 year prior entry study without evidence recurrent malignant disease , exclude patient basal cell carcinoma skin ; superficial carcinoma bladder ; carcinoma prostate current PSA &lt; 0.1 ng/ml ; cervical intraepithelial neoplasia Patients history significant cardiovascular , neurological , endocrine , gastrointestinal , respiratory inflammatory illness could preclude participation trial , pose undue medical hazard interfere interpretation trial result , include , limited , patient congestive heart failure ( NYHA Class 3 4 ) ; unstable angina ; cardiac arrhythmia ; recent ( within precede 6 month ) myocardial infarction stroke ; hypertension require &gt; 2 medication adequate control ; diabetes mellitus &gt; 2 episode ketoacidosis precede 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hodgkin 's Lymphoma</keyword>
	<keyword>HDAC</keyword>
	<keyword>4SC-201</keyword>
	<keyword>Resminostat</keyword>
	<keyword>Phase II</keyword>
</DOC>